MG
AMLX icon

Marex Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Marex Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$128K – 851
2025
Q2 		$128K Hold
20,000
– – ﹤0.01% 550
2025
Q1 		$70.8K Hold
20,000
– – ﹤0.01% 630
2024
Q4 		$75.6K Sell
20,000
-20,000
-50% -$94.1K ﹤0.01% 629
2024
Q3 		$130K Buy
+40,000
New +$89.9K ﹤0.01% 517

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marex Group's AMLX Position: Q3 2025 in Review

Marex Group sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 20,000 shares — an estimated $128K sold.

Marex Group first reported a position in AMLX in Q3 2024 and held it in 4 quarters. The position peaked at $130K in Q3 2024. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Marex Group reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Marex Group sold 20,000 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $128K.
  • Marex Group first reported a position in Amylyx Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Marex Group's Amylyx Pharmaceuticals position peaked at $130K in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.